Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Chemomab Therapeutics ( (CMMB) ).
On July 25, 2025, Chemomab Therapeutics Ltd. announced a Sales Agreement with LifeSci Capital, LLC, allowing the company to offer and sell its American Depositary Shares (ADSs) through an ‘at the market offering’ for up to $7,258,687. This agreement provides Chemomab with flexibility in raising capital, potentially impacting its financial strategy and market positioning, although the company is not obligated to sell any shares and the agreement can be terminated by either party.
The most recent analyst rating on (CMMB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Chemomab Therapeutics stock, see the CMMB Stock Forecast page.
Spark’s Take on CMMB Stock
According to Spark, TipRanks’ AI Analyst, CMMB is a Underperform.
Chemomab Therapeutics’ overall stock score is low due to significant financial challenges, including zero revenue and sustained losses. The technical analysis indicates mixed signals but does not currently show strong upward trends. The valuation metrics reflect high risk without profitability or income generation. The company’s future performance heavily relies on its ability to develop and commercialize products successfully.
To see Spark’s full report on CMMB stock, click here.
More about Chemomab Therapeutics
Chemomab Therapeutics Ltd. is a biotechnology company based in Tel Aviv, Israel, focusing on the development of therapeutics for fibrotic and inflammatory diseases. The company is involved in the biopharmaceutical industry, with a particular emphasis on innovative treatments for conditions with significant unmet medical needs.
Average Trading Volume: 152,389
Technical Sentiment Signal: Sell
Current Market Cap: $20.56M
Find detailed analytics on CMMB stock on TipRanks’ Stock Analysis page.